Transactions & Cas
Schellenberg Wittmer advises Santhera Pharmaceuticals in exclusive License Agreement with Polyphor
15.02.2018
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for orphan and other diseases with high unmet medical needs. On 15 January 2018, Santhera Pharmaceuticals announced that it had entered into an agreement with Polyphor Ltd. for POL6014, a clinical stage selective inhibitor of human neutrophil elastase with the potential to treat cystic fibrosis (CF) and other pulmonary diseases.
Under the agreement, Santhera obtains the worldwide, exclusive rights to develop and commercialize POL6014, for an initial payment of CHF 6.5 million and additional cash payments of up to CHF 121 million contingent to future development, regulatory and particularly sales milestones.
Schellenberg Wittmer is advising Santhera Pharmaceuticals on this matter.
The team consists of Philipp Groz (IP / Life Sciences), Pascal Hubli (Corporate/M&A), Michael Nordin and Petra Hess (both Tax).
Téléchargements
View pdfPartager
Schellenberg Wittmer conseille Emerald Technology Ventures dans l'obtention de sa licence FINMA
13.02.2024
Schellenberg Wittmer conseille Carne dans le cadre du transfert des activités de "Fund Management Services" pour tiers de GAM
01.02.2024
Schellenberg Wittmer conseille AXA dans le cadre du regroupement de ses trois fonds immobiliers
30.01.2024